Daniel P. Petrylak, MD, presented “Chemotherapy Trials” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Petrylak, Daniel P. “Chemotherapy Trials” January 23rd, 2020. Accessed Jul 2020. https://grandroundsinurology.com/prostate-cancer-chemotherapy-trials/
Chemotherapy Trials – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut, discusses data from recent chemotherapy trials for castrate-resistant prostate cancer (CRPC). Dr. Petrylak specifically examines trials evaluating drug combinations as treatment for CRPC patients. Additionally, he reviews the effectiveness of PARP inhibitors in patients with DNA repair mutations. Finally, he notes the apparent superiority of cabazitaxel to NG AA treatment after progression on docetaxel.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Petrylak gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.